Navigation Links
Reference Lab Interface (RLI)©

ProductsReference Lab Interface (RLI)©
Company MedMatics, LLC.
Item Reference Lab Interface (RLI)©
Features 
  • Can review and sign-off digitally, as well as route the message for follow-up processing dependent upon office workflow.
  • Through the use of custom forms, can graphically trend critical result values over time to ensure treatment and medications are having their desired effect.
Description Reference Lab Interface (RLI)© for SRS Software, provides real-time processing of HL7 lab data directly into SRS Freedom Chart ManagerTM, producing an HTML form in the patients chart/tab, while automatically messaging the ordering physician.
Info MedMatics, LLC.
Customer Service: (845) 727-0200

Related medicine products :

1. Clearview hCG Combo w/ Reference Line
2. National Reference Laboratory Services
3. The Clinical Reference Laboratories at National Jewish Medical and Research Center
4. Dermatology, Allergy and Clinical Immunology (DACI) Reference Laboratory
5. Marquette Clinical and Reference Laboratory
6. IBT Reference Laboratory
7. Histopathology Reference Laboratory
8. Clinical Reference Laboratory (CRL)
9. The Reference Laboratory at the Cleveland Clinic
10. RDL Reference Laboratory
11. AMS Reference Lab
Other Medicine News:Health News:Rudd Report Gives AMDL, Inc. a Strong Buy Recommendation in Year-End Financial Research Report 2Health News:Specialists On Call Expands Access to Emergency Neurology On-Call Services in North Carolina 2Health News:INTEGRIS Health Selects Allscripts Care Management for Its 13 Hospitals 2Health News:INTEGRIS Health Selects Allscripts Care Management for Its 13 Hospitals 3Health News:INTEGRIS Health Selects Allscripts Care Management for Its 13 Hospitals 4Health News:INTEGRIS Health Selects Allscripts Care Management for Its 13 Hospitals 5Health News:INTEGRIS Health Selects Allscripts Care Management for Its 13 Hospitals 6Health News:Solos Endoscopy, Inc. Receives Purchase Order from Cleveland Clinic 2Health News:Health Care Spending in U.S. Grew at Lowest Rate in a Decade 2Health News:Health Care Spending in U.S. Grew at Lowest Rate in a Decade 3Health News:CVS/pharmacy Offers Shoppers More Than $69 Million in 'Extra Bucks' 2Health News:CVS/pharmacy Offers Shoppers More Than $69 Million in 'Extra Bucks' 3
Breaking Medicine Technology:Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 2Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 3Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 4Octapharma USA Announces FDA Approval of wilate(R) - the First Replacement Therapy Developed Specifically for von Willebrand Disease 5Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 2Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 3Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 4Stallergenes: Oralair: Very Positive 3-Year Results of the Long-Term Study 5Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 2Q-Med AB and Oceana Therapeutics, Inc. Take Major Step Towards SOLESTA(TM) US Regulatory Filing 3Want to Stop Cancer 3F You Can Experts Say 47763 1Want to Stop Cancer 3F You Can Experts Say 47763 2Want to Stop Cancer 3F You Can Experts Say 47763 3New Ad Campaign Asks D C Commuters Whos Hogging Our Antibiotics 3F 47760 1New Ad Campaign Asks D C Commuters Whos Hogging Our Antibiotics 3F 47760 2Lilly Resubmits Cymbalta 28R 29 Supplemental New Drug Application for Chronic Pain to U S Food and Drug Administration 47758 1Lilly Resubmits Cymbalta 28R 29 Supplemental New Drug Application for Chronic Pain to U S Food and Drug Administration 47758 2Lilly Resubmits Cymbalta 28R 29 Supplemental New Drug Application for Chronic Pain to U S Food and Drug Administration 47758 3Lilly Resubmits Cymbalta 28R 29 Supplemental New Drug Application for Chronic Pain to U S Food and Drug Administration 47758 4